- Home
- IOBT vs MGNX Comparison
IOBT vs MGNX Comparison
Compare IOBT & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IOBT
- MGNX
- Stock Information
- Founded
- IOBT 2014
- MGNX 2000
- Country
- IOBT Denmark
- MGNX United States
- Employees
- IOBT N/A
- MGNX N/A
- Industry
- IOBT Biotechnology: Pharmaceutical Preparations
- MGNX Biotechnology: Pharmaceutical Preparations
- Sector
- IOBT Health Care
- MGNX Health Care
- Exchange
- IOBT Nasdaq
- MGNX Nasdaq
- Market Cap
- IOBT 114.6M
- MGNX 99.7M
- IPO Year
- IOBT 2021
- MGNX 2013
- Fundamental
- Price
- IOBT $1.62
- MGNX $1.73
- Analyst Decision
- IOBT Strong Buy
- MGNX Hold
- Analyst Count
- IOBT 2
- MGNX 6
- Target Price
- IOBT $8.00
- MGNX $3.20
- AVG Volume (30 Days)
- IOBT 1.1M
- MGNX 1.0M
- Earning Date
- IOBT 11-11-2025
- MGNX 11-04-2025
- Dividend Yield
- IOBT N/A
- MGNX N/A
- EPS Growth
- IOBT N/A
- MGNX N/A
- EPS
- IOBT N/A
- MGNX N/A
- Revenue
- IOBT N/A
- MGNX $165,495,000.00
- Revenue This Year
- IOBT N/A
- MGNX N/A
- Revenue Next Year
- IOBT N/A
- MGNX N/A
- P/E Ratio
- IOBT N/A
- MGNX N/A
- Revenue Growth
- IOBT N/A
- MGNX 303.47
- 52 Week Low
- IOBT $0.66
- MGNX $0.99
- 52 Week High
- IOBT $2.79
- MGNX $5.10
- Technical
- Relative Strength Index (RSI)
- IOBT 44.35
- MGNX 53.47
- Support Level
- IOBT $1.71
- MGNX $1.46
- Resistance Level
- IOBT $2.08
- MGNX $1.77
- Average True Range (ATR)
- IOBT 0.15
- MGNX 0.16
- MACD
- IOBT -0.01
- MGNX -0.03
- Stochastic Oscillator
- IOBT 16.36
- MGNX 35.53
About IOBT IO Biotech Inc.
IO Biotech Inc is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on T-win technology platform. The product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression.
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.